Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston. On May 21 from 11am – 1pm ET, Dr. Grossman will co-lead a workshop discussion titled, “Naviga